ClassID:

110379

C12N2740/15041 - CPC Classification

Classification description:

Reverse transcribing RNA viruses; Details; Retroviridae; Lentivirus, not HIV, e.g. FIV, SIV Use of virus, viral particle or viral elements as a vector

Sub-classes:
Recent Application in this class:
#1
20260117181
2026-04-30

ERRalpha GENE KNOCKOUT ERYTHROID PROGENITOR CELLS AND METHODS OF ERYTHROID DIFFERENTIATION THEREOF

#2
20260022403
2026-01-22

VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME

#3
20260009000
2026-01-08

METHODS FOR TRANSDUCING IMMUNE CELLS

#4
20250295774
2025-09-25

COMPOSITIONS AND METHODS FOR GENERATING A PERSISTING POPULATION OF T CELLS USEFUL FOR THE TREATMENT OF CANCER

#5
20250179523
2025-06-05

METHODS FOR THE PURIFICATION OF VIRAL VECTORS

#6
20250134941
2025-05-01

HSV-1 ONCOLYTIC VIRUS THERAPIES THAT SPECIFICALLY KILL ALT DEPENDENT CANCERS

#7
20250122533
2025-04-17

VIRAL VECTORS AND PACKAGING CELL LINES

#8
20250122532
2025-04-17

VIRAL VECTORS AND PACKAGING CELL LINES

#9
20250121005
2025-04-17

CAR and Polyspecific Binding Molecules Targeting Solid Tumors

#10
20250092362
2025-03-20

System And Methods For Producing Chimeric Antigen Receptor Cells

#11
20250064852
2025-02-27

CD5 Modified Cells Comprising Chimeric Antigen Receptors (CARs) for Treatment of Solid Tumors

#12
20250057882
2025-02-20

Transgenic Immune Cell, Construction Method Therefor and Use Thereof

#13
20250011461
2025-01-09

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

#14
20250009801
2025-01-09

COMBINATION OF MOLECULAR SWITCH REGULATION TYPE CHIMERIC ANTIGEN RECEPTOR CELL AND ANTIBODY, AND USE THEREOF

#15
20240309102
2024-09-19

Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy

#16
20240299543
2024-09-12

SELF-POLARIZING IMMUNE CELLS

#17
20240294662
2024-09-05

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

#18
20240254511
2024-08-01

NUCLEIC ACID CONSTRUCTS ENCODING REPROGRAMMING FACTORS LINKED BY SELF-CLEAVING PEPTIDES

#19
20240254178
2024-08-01

DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATION

#20
20240252615
2024-08-01

PRE-IMMUNIZATION AND IMMUNOTHERAPY

#21
20240252536
2024-08-01

CHIMERIC ANTIGEN RECEPTORS AND MODIFIED CELLS COMPRISING THE SAME

#22
20240240147
2024-07-18

CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY

#23
20240228547
2024-07-11

POLYPEPTIDE FOR RESISTING NOVEL CORONAVIRUS AND APPLICATION THEREOF

#24
20240209039
2024-06-27

NOVEL POLYPEPTIDE EXHIBITING FLUORESCENT PROPERTIES AND USE FOR SAME

#25
20240052311
2024-02-15

END-TO-END CELL THERAPY AUTOMATION

#26
20230346835
2023-11-02

CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND USE THEREOF

#27
20230313193
2023-10-05

METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES

#28
20230304037
2023-09-28

METHODS FOR PRODUCING CLINICAL-GRADE LENTIVIRAL VECTOR

#29
20230285591
2023-09-14

NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE

#30
20230242621
2023-08-03

ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF

#31
20230241166
2023-08-03

ULTRA-SENSITIVE STEP-FUNCTION OPSIN FOR MINIMALLY INVASIVE OPTOGENETIC STIMULATION

#32
20230235285
2023-07-27

TARGETING BCL11A ENHANCER FUNCTIONAL REGIONS FOR FETAL HEMOGLOBIN REINDUCTION

#33
20230233654
2023-07-27

GENE EDITING METHODS AND COMPOSITIONS FOR ELIMINATING RISK OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY

#34
20230220416
2023-07-13

NOVEL TRANSDUCTION ENHANCERS AND USES THEREOF

#35
20230212607
2023-07-06

IMPROVED LENTIVIRAL EXPRESSION VECTOR, CONSTRUCTION METHOD FOR SAME, AND APPLICATIONS THEREOF

#36
20230183371
2023-06-15

ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF

#37
20230132355
2023-04-27

Delivery of card protein as therapy for ocular inflammation

#38
20230117384
2023-04-20

COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY

#39
20230026345
2023-01-26

METHODS AND CONSTRUCTS FOR TRANSIENT PRODUCTION OF LENTIVIRAL VECTOR

#40
20230000948
2023-01-05

Compositions and methods for treatment of GCase related disease states

#41
20220411818
2022-12-29

IMPROVED IN VIVO REPROGRAMMING SYSTEM AND CELL CONVERSION METHOD USING SAME

#42
20220282214
2022-09-08

End-to-end cell therapy automation

#43
20220282213
2022-09-08

End-to-end cell therapy automation

#44
20220282212
2022-09-08

END-TO-END CELL THERAPY AUTOMATION

#45
20220267731
2022-08-25

ANTI-ROBO1 CAR-T CELL, AND PREPARATION AND APPLICATION THEREOF

#46
20220249556
2022-08-11

METHODS FOR TRANSDUCING IMMUNE CELLS

#47
20220228117
2022-07-21

METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE

#48
20220056116
2022-02-24

Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer

#49
20220033849
2022-02-03

Methods for the purification of viral vectors

#50
20220025363
2022-01-27

SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

#51
20210361751
2021-11-25

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

#52
20210309966
2021-10-07

Methods of improving vector transduction efficiency into T lymphocytes

#53
20210222200
2021-07-22

Compositions and methods for hemoglobin production

#54
20210163621
2021-06-03

Chimeric receptors to DLL3 and methods of use thereof

#55
20210154231
2021-05-27

METHOD FOR PRODUCING T CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR

#56
20210147871
2021-05-20

Viral vectors and packaging cell lines

#57
20210130479
2021-05-06

Compositions and methods for treating cancer with anti-CD123 immunotherapy

#58
20200407460
2020-12-31

Human mesothelin chimeric antigen receptors and uses thereof

#59
20200353042
2020-11-12

Compositions and methods for treatment of GCASE related disease states

#60
20200306348
2020-10-01

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

#61
20200140867
2020-05-07

Compositions and methods for the treatment of myotonic dystrophy

#62
20200080090
2020-03-12

SELF-LIMITING CAS9 CIRCUITRY FOR ENHANCED SAFETY (SLICES) PLASMID AND LENTIVIRAL SYSTEM THEREOF

#63
20200071670
2020-03-05

End-to-end cell therapy automation

#64
20200032292
2020-01-30

Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides

#65
20200017828
2020-01-16

Human neural precursor cells with inducible STIM1 knockdown

#66
20200010555
2020-01-09

Compositions and methods for treating cancer with anti-CD123 immunotherapy

#67
20190358297
2019-11-28

ANGIOGENIC CONDITIONING TO ENHANCE CARDIAC CELLULAR REPROGRAMMING OF FIBROBLASTS OF THE INFARCTED MYOCARDIUM

#68
20190350978
2019-11-21

PRODUCTION OF ENGINEERED CELLS FOR ADOPTIVE CELL THERAPY

#69
20190338280
2019-11-07

IMMUNOMODULATION BY CONTROLLING ELR+ PROINFLAMMATORY CHEMOKINE LEVELS WITH THE LONG NON-CODING RNA UMLILO

#70
20190316153
2019-10-17

Packaging cell for making a pseudotyped lentivirus

#71
20190284533
2019-09-19

VCN enhancer compositions and methods of using the same

#72
20190262398
2019-08-29

TIM3 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE

#73
20190247470
2019-08-15

Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy

#74
20190194615
2019-06-27

T cell compositions

#75
20190169572
2019-06-06

End-to-end cell therapy automation

#76
20190127696
2019-05-02

Anti-ROBO1 CAR-T cell, and preparation and application thereof

#77
20190125898
2019-05-02

Nipah virus envelope pseudotyped lentiviruses and methods of their use

#78
20190093126
2019-03-28

Large commercial scale lentiviral vector production system and vectors produced thereby

#79
20190085063
2019-03-21

Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

#80
20190060427
2019-02-28

Methods and compositions for sustained immunotherapy

#81
20190055518
2019-02-21

Method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors

#82
20190046594
2019-02-14

HSV-1 oncolytic virus therapies that specifically kill ALT dependent cancers

#83
20190038705
2019-02-07

OPTICALLY-BASED STIMULATION OF TARGET CELLS AND MODIFICATIONS THERETO

#84
20190022027
2019-01-24

Reprogramming-based models of neurodevelopmental disorders and uses thereof

#85
20180371068
2018-12-27

Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer

#86
20180344816
2018-12-06

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

#87
20180318447
2018-11-08

Compositions and methods for improving viral vector efficiency

#88
20180258389
2018-09-13

Methods of generating neural stem cells

#89
20180228867
2018-08-16

Compositions and methods for treatment of Gcase related disease states

#90
20180223313
2018-08-09

Lentiviral protein delivery system for RNA-guided genome editing

#91
20180179555
2018-06-28

Methods of delivering a pseudotyped lentivirus

#92
20180177866
2018-06-28

HIV pre-immunization and immunotherapy

#93
20180177858
2018-06-28

Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins

#94
20180171297
2018-06-21

Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction

#95
20180057795
2018-03-01

Methods of producing modified natural killer cells and methods of use

#96
20170349898
2017-12-07

IMMUNOMODULATION BY CONTROLLING ELR+ PROINFLAMMATORY CHEMOKINE LEVELS WITH THE LONG NON-CODING RNA UMLILO

#97
20170267978
2017-09-21

INDUCED PLURIPOTENT STEM CELLS

#98
20170252402
2017-09-07

METHODS FOR TREATING TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA WITH APOLIPOPROTEIN D

#99
20170215392
2017-08-03

Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo

#100
20170166866
2017-06-15

Methods of improving vector transduction efficiency into T lymphocytes

#101
20170080050
2017-03-23

Optically-based stimulation of target cells and modifications thereto

#102
20170056527
2017-03-02

Thymidylate kinase fusions and uses thereof

#103
20170056467
2017-03-02

Optically-based stimulation of target cells and modifications thereto

#104
20170049861
2017-02-23

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

#105
20170016005
2017-01-19

Pharmaceutical composition and method for reducing scar formation

#106
20160340692
2016-11-24

Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein

#107
20160311917
2016-10-27

Human mesothelin chimeric antigen receptors and uses thereof

#108
20160304869
2016-10-20

Materials and methods for treatment of pulmonary arterial hypertension

#109
20160017012
2016-01-21

Delivery of card protein as therapy for occular inflammation

#110
20150368646
2015-12-24

Compositions and methods for treating pancreatic cancer

#111
20150352181
2015-12-10

Methods for treating tissue damage associated with ischemia with apolipoprotein D

#112
20150322416
2015-11-12

Enhancing health in mammals using telomerase reverse transcriptase gene therapy

#113
20150290290
2015-10-15

Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium

#114
20150175667
2015-06-25

Method of stimulating an immune response using a pseudotyped lentivirus

#115
20150125536
2015-05-07

Methods and compositions for sustained immunotherapy

#116
20150118714
2015-04-30

Vectors for transgene expression

#117
20150087068
2015-03-26

Methods of genetically modifying animal cells

#118
20150050242
2015-02-19

Nipah virus envelope pseudotyped lentiviruses and methods of their use

#119
20150030617
2015-01-29

Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs

#120
20150004703
2015-01-01

SINGLE LENTIVIRAL VECTOR SYSTEM FOR INDUCED PLURIPOTENT (IPS) STEM CELLS DERIVATION

#121
20140356905
2014-12-04

Mammalian Cell Culture System for Large-Scale Expression of Recombinant Proteins

#122
20140350085
2014-11-27

Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitro

#123
20140349403
2014-11-27

LARGE COMMERCIAL SCALE LENTIVIRAL VECTOR PRODUCTION SYSTEM AND VECTORS PRODUCED THEREBY

#124
20140308255
2014-10-16

Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming

#125
20140178426
2014-06-26

Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins

#126
20140120132
2014-05-01

Lentiviral vectors containing an MHC class I promoter

#127
20140050725
2014-02-20

Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs

#128
20130195812
2013-08-01

Induced pluripotent stem cells

#129
20120070462
2012-03-22

Targeted gene delivery to dendritic cells

#130
20120028821
2012-02-02

Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides

#131
20110311489
2011-12-22

Optically-based stimulation of target cells and modifications thereto

#132
20110236966
2011-09-29

Single lentiviral vector system for induced pluripotent (iPS) stem cells derivation

#133
20110104130
2011-05-05

Thymidylate kinase fusions and uses thereof

#134
20100120140
2010-05-13

Recombiant lentivirus comprising an E2 alphavirus glycoprotein that binds to DC-SIGN

#135
20100120122
2010-05-13

Packaging cells for producing retrovirus pseudotyped with an E2 alphavirus glycoprotein

#136
20080019998
2008-01-24

Targeted gene delivery for dendritic cell vaccination